In vitro removal of anti-infective agents by a novel cytokine adsorbent system

Abstract

Objectives:

The aim of this study is to describe the in vitro adsorption of anti-infective drugs onto an extracorporeal cytokine adsorber.

Methods:

Various anti-infective drugs (β-lactams, quinolones, aminoglycosides, glycopeptides, azole antimycotics) were prepared in normal saline 0.9% and human albumin 5%, and pumped through a cytokine cartridge (CytoSorb^®; CytoSorbents Corporation, Monmouth Junction, NJ, USA) at a flow rate of 1.2 L/h for 1.5 h. In addition, meropenem and ciprofloxacin were dissolved in reconstituted blood and run through a CytoSorb cartridge, which was integrated into a continuous renal replacement therapy circuit with a flow rate of 2 L/h for 18 h. Samples from the solution, pre- and post-filter, were quantified by high-performance liquid chromatography with ultraviolet detection and fluorescence polarisation immunoassay.

Results:

Observed mean clearance of the drugs in normal saline was 1.22 ± 0.07 L/h. In human albumin, clearance was 1.29 ± 0.08 L/h. In reconstituted blood, clearance of meropenem decreased from 5.4 to 1.4 L/h and for ciprofloxacin from 6.3 to 4.3 L/h within the first 1.5 h because of early drug adsorption. Continuous renal replacement therapy clearance measured without CytoSorb was stable at 2 and 1.7 L/h, respectively. Approximately 400 mg of meropenem and 300 mg of ciprofloxacin had been adsorbed by CytoSorb, suggesting that these amounts are the maximum adsorptive capacity for these drugs.

Conclusion:

In these settings, all tested drugs were adsorbed by the cartridge in relevant amounts. The identified maximum adsorptive capacity and the rapid decline in concentration during the first 1.5 h of CytoSorb use suggest that the administration of an additional dose within the first hours of CytoSorb treatment may be reasonable. In addition, early therapeutic drug monitoring should be considered.

Keywords

Antibiotic pharmacokinetic cytokine adsorber extracorporeal elimination

Get full access to this article

View all access options for this article.

References

Kellum

Venkataraman

Powner

et al . Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med 2008; 36: 268–272.

Peng

Z-Y

Carter

Kellum

JA.

Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med 2008; 36: 1573–1577.

Honore

Jacobs

Joannes-Boyau

et al . Newly designed CRRT membranes for sepsis and SIRS – a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO 2013; 59: 99–106.

Basu

Pathak

Goyal

et al . Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: a case study. Indian J Crit Care Med 2014; 18: 822–824.

Bruenger

Kizner

Weile

et al . First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report. Int J Artif Organs 2015; 38: 113–116.

Houschyar

Pyles

Rein

et al . Continuous hemoadsorption with a cytokine adsorber during sepsis – a review of the literature. Int J Artif Organs 2017; 40: 205–211.

Träger

Schütz

Fischer

et al . Cytokine reduction in the setting of an ARDS-associated inflammatory response with multiple organ failure. Case Rep Crit Care 2016; 2016: 9852073.

Friesecke

Träger

Schittek

et al . International registry on the use of the CytoSorb^® adsorber in ICU patients: study protocol and preliminary results. Med Klin Intensivmed Notfmed 2017: 1–9.

U.S. Department of Health and Human Services, Food and Drug Administation, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Bioanalytical Method Validation Guidance for Industry, 2018.

10.

Roehr

Frey

Koeberer

et al . Anti-infective drugs during continuous hemodialysis – using the bench to learn what to do at the bedside. Int J Artif Organs 2015; 38: 17–22.

11.

Kielstein

Czock

Schöpke

et al . Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006; 34: 51–56.

12.

Ashley

Dunleavy

Wheeler

(eds). The renal drug handbook: the ultimate prescribing guide for renal practitioners. 4th ed. London: Radcliffe Publishing Ltd., 2014.

13.

National Center for Biotechnology Information. The PubChem Compound Database, https://pubchem.ncbi.nlm.nih.gov/ (accessed 19 November 2018).

14.

Reiter

Bordoni

Dall’Olio

et al . In vitro removal of therapeutic drugs with a novel adsorbent system. Blood Purif 2002; 20: 380–388.

15.

Røder

Frimodt-Møller

Espersen

et al . Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration. Infection 1995; 23: 107–112.

16.

Nicholson

Wolmarans

Park

GR.

The role of albumin in critical illness. Br J Anaesth 2000; 85: 599–610.

17.

Ulldemolins

Soy

Llaurado-Serra

et al . Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother 2015; 59: 5520–5528.

18.

Sörgel

Höhl

Glaser

et al . Pharmacokinetics and pharmacodynamics of antibiotics in intensive care. Med Klin Intensivmed Notfmed 2017; 112: 11–23.

19.

Brinkmann

Röhr

Köberer

et al . Therapeutic drug monitoring and individual dosing of antibiotics during sepsis: modern or just ‘trendy’? Med Klin Intensivmed Notfmed 2018; 113: 82–93.

20.

Lelubre

Vincent

J-L.

Red blood cell transfusion in the critically ill patient. Ann Intensive Care 2011; 1: 43.